| *Disseminated on Behalf of Cardiol Therapeutics Inc.
(Nasdaq: CRDL) Goes Green At The Jump Tuesday (New Phase 2 ARCHER Trial Data)
*Click Here To Get Our Alerts Faster Via SMS*
December 2nd Greetings Readers,
Cardiol Therapeutics Inc. (Nasdaq: CRDL) pushes green early Tuesday AM while retaining my top watchlist spot.
This comes on the heels of yesterday's major news announcement. Check it out:
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
- Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.
- Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.
- The ARCHER data strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent pericarditis (MAVERIC) and support broader development across inflammatory cardiac conditions.
- Chronic inflammation is a central driver of adverse cardiac remodeling and heart failure, yet there are currently no approved therapies that directly target this underlying biology.
...
Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced new and comprehensive data from ARCHER, a randomized double-blind, placebo-controlled, multi-center Phase II clinical trial of CardiolRx™ in patients with acute myocarditis. The data show meaningful improvements in cardiac MRI (CMR) measures of myocardial recovery in patients with acute myocarditis, a potentially fatal condition caused by viral infections, autoimmune diseases, immune checkpoint inhibitor therapy to treat cancers, and exposure to cardiotoxic substances.
"The ARCHER results show that CardiolRx™ can drive meaningful structural recovery in the hearts of patients with acute myocarditis," said Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development of Cardiol Therapeutics. "We are seeing in these patients the same beneficial cardiac changes we previously observed in multiple pre-clinical heart failure models, strengthening our confidence in CardiolRx™ as a potential therapy across multiple inflammatory cardiac conditions."
...
The ARCHER data were presented on November 29, 2025, by Dr. Leslie T. Cooper, Jr., Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Florida and Co-Chair of the Steering Committee for the ARCHER trial, at the Annual Meeting of the European Society of Cardiology Working Group on Myocardial & Pericardial Disease in Trieste, Italy.
"ARCHER was an important, well-designed, and well-executed clinical trial. The positive changes in CMR measurements are exciting-most notably the reduction in LV mass, consistent with the numerical reductions in both ECV and ICV," commented Dr. Cooper. "These findings reinforce our original hypothesis that this innovative treatment strategy can attenuate myocardial inflammation and edema. ARCHER's results provide sound rationale for advancing the clinical development of this novel therapy in conditions of the myocardium characterized by edema, fibrosis, and remodeling, including the growing challenge of immune checkpoint inhibitor-induced myocarditis, which can be fatal."
...
Read the full article here.
Don't forget. TipRanks reports that CRDL has 4 analyst targets averaging $8.25. That means CRDL has a potential triple-digit upside from its opening valuation Tuesday.
Spend a second to review my initial report below on (Nasdaq: CRDL) and consider this profile for your watchlist. -----
Progress in cardiovascular medicine is rapidly reshaping care for inflammatory heart disease, an area where treatment choices remain limited and patient need is high.
Work focused on myocarditis and pericarditis is steadily advancing, with early data and active clinical programs pointing toward more meaningful options for people living with these difficult conditions.
At the center of this effort is a clinical-stage life sciences company guided by an experienced leadership team that includes former Amgen and Eli Lilly executives and a focused mandate to address critical gaps in cardiac treatment.
With multiple initiatives emerging, including those aimed at heart failure, the group’s growing footprint across the heal-thcare sector is turning its progress into a key development for observers of innovation in heart care.
And with promising advances in its Phase 2 ARCHER trial, strong patent protection securing their competitive position, and several analyst targets suggesting potential triple-digit upside, this under-the-radar Nasdaq profile tops our watchlist Tuesday:
*Cardiol Therapeutics Inc. (Nasdaq: CRDL)*
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
And based on several potential catalysts, (Nasdaq: CRDL) takes over Tuesday's watchlist's top spot. Check them out:
#1. Advancing Therapies That Target Inflammation In The Heart!
#2. Promising Advances In Myocarditis Treatment Strengthen Future Outlook.
#3. Cardiol Therapeutics Secures Broad Patent Protection Through Late 2040.
#4. Cardiol Therapeutics Announce Phase 2 Results For ARCHER.
#5. Multiple Analyst Targets Point To Triple-Digit Potential Upside!
But more on those in a second...
Cardiol's Immediate Focus
The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.
Pericarditis
Pericarditis is the most common pericardial disease, responsible for about 5% of emergency room admissions for chest pain in North America and Western Europe. Recurrent pericarditis is the re-appearance of symptoms after a symptom-free period of at least 4 – 6 weeks following an initial acute episode of pericarditis. Recurrent pericarditis develops in 15–30% of cases, impacting nearly ~38,000 patients annually. Each hospitalization can cost $20k–$30k, creating a significant burden.
Patients face sharp chest pain, fatigue, and repeat hospital stays, with rare but serious complications like tamponade and constrictive pericarditis. The only FDA-approved treatment, rilonacept, costs over $270k per year. Options remain limited, underscoring the urgent need for new therapies.
Cardiol’s MAVERIC program for recurrent pericarditis has two parts. The first, a Phase 2 study, is already completed. The second is a pivotal Phase 3 trial currently enrolling patients across approximately 20 sites in the US, Canada, and Europe. This global, randomized, double-blind, placebo-controlled study is designed to determine whether CardiolRx™ can prevent disease recurrence in high-risk patients and support regulatory approval. -----
Myocarditis
Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is when the heart muscle gets inflamed. It can cause chest pain, trouble with how the heart works, and abnormal heart rhythms. In some cases, it can lead to severe heart failure or even sudden death, especially in people under 35.
Most often, it’s caused by a vi-rus, but it can also come from bacteria, certain medications, mRNA vaccines, or cancer treatments like chemotherapy and immune- based drugs.
CardiolRx™ was tested in the ARCHER trial, a Phase 2 study which took place in the US, Canada, Brazil, France, and Israel. The goal was to see if the drug is safe, well tolerated, and helps the heart recover in people with acute myocarditis. The full results were just announced! -----
Heart Failure
Heart failure affects more than 6.7Mn people in the U.S. and associated heal.thcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is when the heart can’t pump enough blood and oxygen for the body. This can cause shortness of breath, a fast heartbeat, swelling, low energy, and trouble doing everyday activities. Many people with heart failure end up in the hospital often, and it can greatly affect quality of life.
It can be caused by heart attacks, high blood pressure, heart valve problems, heart inflammation (like myocarditis), certain cancer treatments, or inherited conditions. CRD-38 is Cardiol’s new subcutaneously administered drug formulation targeting heart failure caused by inflammation. They’re doing the prep work needed before starting clinical trials to see if it can become a new treatment option. -----
Product Pipeline | 
0 التعليقات:
إرسال تعليق